369 related articles for article (PubMed ID: 7678882)
21. Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
Messinger Y; Reaman GH; Ek O; Uckun FM
Leuk Lymphoma; 1999 Apr; 33(3-4):289-93. PubMed ID: 10221508
[TBL] [Abstract][Full Text] [Related]
22. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
Messinger Y; Yanishevski Y; Avramis VI; Ek O; Chelstrom LM; Gunther R; Myers DE; Irvin JD; Evans W; Uckun FM
Clin Cancer Res; 1996 Sep; 2(9):1533-42. PubMed ID: 9816330
[TBL] [Abstract][Full Text] [Related]
23. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
[TBL] [Abstract][Full Text] [Related]
24. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
Yoshida M; Rybak RJ; Choi Y; Greenberg SJ; Barcos M; Kawata A; Matsuno F; Tsai H; Seon BK
Cancer Res; 1997 Feb; 57(4):678-85. PubMed ID: 9044845
[TBL] [Abstract][Full Text] [Related]
25. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
[TBL] [Abstract][Full Text] [Related]
26. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
[TBL] [Abstract][Full Text] [Related]
27. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
28. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
29. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma.
Ek O; Waurzyniak B; Myers DE; Uckun FM
Clin Cancer Res; 1998 Jul; 4(7):1641-7. PubMed ID: 9676838
[TBL] [Abstract][Full Text] [Related]
31. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
33. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
[TBL] [Abstract][Full Text] [Related]
34. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
[TBL] [Abstract][Full Text] [Related]
36. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA
J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241
[TBL] [Abstract][Full Text] [Related]
37. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
39. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Ek O; Gaynon P; Zeren T; Chelstrom LM; Myers DE; Uckun FM
Leuk Lymphoma; 1998 Sep; 31(1-2):143-9. PubMed ID: 9720724
[TBL] [Abstract][Full Text] [Related]
40. Visualization of immunotoxin-mediated tumor cell death in vivo.
Erickson HA; Reinhardt RL; Hermanson JB; Panoskaltsis-Mortari A; Pennell CA
Clin Cancer Res; 2001 Mar; 7(3 Suppl):890s-894s. PubMed ID: 11300488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
